Table 2

Clinical and biological characteristics of NB patients with RASSF1A methylation

CharacteristicNo. of patient (%)10-year OS rate (95% CI)P*
Sex0.33
 Male31 (50.8)60% (42–77)
 Females30 (49.2)72% (54–90)
Age at diagnosis0.02
 <1 year25 (40.9)84% (69–98)
 ≥1 year36 (59.0)51% (34–69)
Pathology0.12
 GNR5 (8.2)100%
 GNB5 (8.2)100%
 NB51 (83.5)59% (45–73)
Stage<0.0001
 117 (27.9)91% (74–100)
 26 (9.8)100%
 312 (19.7)83% (62–100)
 423 (37.7)28% (9–47)
 4s3 (4.9)67% (13–100)
MYCN 0.09
 Amplified16 (26.2)49% (24–74)
 Nonamplified45 (73.8)72% (58–85)
Risk group<0.001
 Nonhigh-risk41 (67.2)86% ( 74–97)
 High-risk20 (32.8)23% (4–42)
TSP-1 0.85
 Unmethylated27 (44.3)64% (43–84)
 Methylated34 (55.7)60% (43–78)
RASSF1A 0.001
 Unmethylated22 (36.1)94% (82–100)
 Methylated39 (63.9)50% (34–66)
  • Abbreviations: OS, overall survival; GNR, ganglioneuroma.

  • * Log-rank test.